[Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Anti-tumor drugs have been the mainstay of cancer treatment; however, immunotherapy has been considered as supplementary, often less effective, and associated with toxicity. However, over the recent years, new types of immunotherapies have been developed, some of which are proving pivotal in current cancer treatment. Of these, chimeric antigen receptor T (CAR-T) cell therapy represents one of the promising types of immunotherapy, particularly for B-lineage malignancy treatment. Notably, many researchers are utilizing this technology for other types of cancer as well. Although it has some drawbacks such as lethal side-effects and extremely high costs, CAR-T cell therapy is estimated to be a potential game changer in the field of cancer treatment. This review provides an overview of the current status and future prospects of CAR-T therapy.